By Colin Kellaher

Alnylam Pharmaceuticals Inc. (ALNY) and Sanofi (SNY) on Sunday said they agreed to restructure their RNAi therapeutics alliance to streamline and optimize development of certain products for the treatment of rare genetic diseases.

As part of the restructuring, Cambridge, Mass., biopharmaceutical company Alnylam will obtain global development and commercialization rights to its investigational RNAi therapeutics programs for the treatment of ATTR amyloidosis, including patisiran and ALN-TTRsc02, while Sanofi obtains global development and commercialization rights to fitusiran, an investigational therapeutic in development for the treatment of hemophilia A and B.

France's Sanofi will receive royalties based on net sales of the ATTR amyloidosis products, and Alnylam will receive royalties based on sales of fitusiran products.

The companies said terms of their 2014 agreement with respect to other products under the alliance are unchanged.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 07, 2018 15:44 ET (20:44 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sanofi Charts.